These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
37 related articles for article (PubMed ID: 26032359)
21. LW-213 induces G2/M cell cycle arrest through AKT/GSK3β/β-catenin signaling pathway in human breast cancer cells. Zhao L; Miao HC; Li WJ; Sun Y; Huang SL; Li ZY; Guo QL Mol Carcinog; 2016 May; 55(5):778-92. PubMed ID: 25945460 [TBL] [Abstract][Full Text] [Related]
22. Myricetin suppresses p21-activated kinase 1 in human breast cancer MCF-7 cells through downstream signaling of the β-catenin pathway. Jiao D; Zhang XD Oncol Rep; 2016 Jul; 36(1):342-8. PubMed ID: 27122002 [TBL] [Abstract][Full Text] [Related]
23. [Effects of glycogen synthase kinase 3β overexpression in rat and glycogen synthase kinase 3β inhibitor SB-216763 on proliferation of hepatic oval cells]. Zhong JQ; Xie YK; Ji XK; Fu JH; Wang Y; Zhang QY; Shi HQ; Shan YF Zhonghua Wai Ke Za Zhi; 2012 Nov; 50(11):1003-6. PubMed ID: 23302485 [TBL] [Abstract][Full Text] [Related]
24. Advanced glycation end-product-inhibited cell proliferation and protein expression of beta-catenin and cyclin D1 are dependent on glycogen synthase kinase 3beta in LLC-PK1 cells. Lin KH; Guh JY; Mo JF; Chiou SJ; Hwang CC; Chuang LY Arch Biochem Biophys; 2008 Sep; 477(1):27-32. PubMed ID: 18474214 [TBL] [Abstract][Full Text] [Related]
25. Brazilein, a compound isolated from Caesalpinia sappan Linn., induced growth inhibition in breast cancer cells via involvement of GSK-3β/β-Catenin/cyclin D1 pathway. Tao LY; Li JY; Zhang JY Chem Biol Interact; 2013 Oct; 206(1):1-5. PubMed ID: 23948132 [TBL] [Abstract][Full Text] [Related]
26. A Bacterial Metabolite, Compound K, Induces Programmed Necrosis in MCF-7 Cells via GSK3β. Kwak CW; Son YM; Gu MJ; Kim G; Lee IK; Kye YC; Kim HW; Song KD; Chu H; Park BC; Lee HK; Yang DC; Sprent J; Yun CH J Microbiol Biotechnol; 2015 Jul; 25(7):1170-6. PubMed ID: 26032359 [TBL] [Abstract][Full Text] [Related]
27. Bioconversion, Pharmacokinetics, and Therapeutic Mechanisms of Ginsenoside Compound K and Its Analogues for Treating Metabolic Diseases. Morshed MN; Akter R; Karim MR; Iqbal S; Kang SC; Yang DC Curr Issues Mol Biol; 2024 Mar; 46(3):2320-2342. PubMed ID: 38534764 [TBL] [Abstract][Full Text] [Related]
28. Ginsenosides in cancer: Targeting cell cycle arrest and apoptosis. Shah MA; Abuzar SM; Ilyas K; Qadees I; Bilal M; Yousaf R; Kassim RMT; Rasul A; Saleem U; Alves MS; Khan H; Blundell R; Jeandet P Chem Biol Interact; 2023 Sep; 382():110634. PubMed ID: 37451663 [TBL] [Abstract][Full Text] [Related]
29. Compound K: A systematic review of its anticancer properties and probable mechanisms. Tam DNH; Nam NH; Cuong NTK; Hung DT; Soa DT; Altom A; Tran L; Elhadad H; Huy NT Fundam Clin Pharmacol; 2023 Aug; 37(4):684-712. PubMed ID: 36691721 [TBL] [Abstract][Full Text] [Related]